CULNEXIN THERAPEUTICS LLC

Princeton Junction, NJ · Biotech · Private

Small molecule drugs that inhibit CUL4A ubiquitin ligase for triple negative breast cancer treatment

Grants
$1.3M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grant· 1 of 2 same dayDepartment of Health and Human Services · Phase I · Small Molecule CUL4 Inhibitors as Dual Precision Oncology and Immuno-Oncology Drugs$399,999
Federal grant· 2 of 2 same dayDepartment of Health and Human Services · Phase I · Small Molecule CUL4 Inhibitors as Dual Precision Oncology and Immuno-Oncology Drugs$646,117
Federal grantDepartment of Health and Human Services · Phase I · Small Molecule CUL4 Inhibitors as Dual Precision Oncology and Immuno-Oncology Drugs$246,118
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2921VINCERE BIOSCIENCES INC——
2922AADI, LLC——
2923NAUTILUS, INC.——
2924CULNEXIN THERAPEUTICS LLC——
2925NewAmsterdam Pharma——
2926TRPBLUE, INC.——
2927Senotrac Biotechnology LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.